title: Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
authors: ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands. m.veltkamp@antoniusziekenhuis.nl.
authors: M
authors: M
authors: Veltkamp
authors: M
authors: M
authors: Drent
authors: R P
authors: RP
authors: Baughman
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D057915:Drug Substitution; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D012507:Sarcoidosis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D059451:Biosimilar Pharmaceuticals; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab